LAMEDITECH signs MOU with Xcell Therapeutics for health and beauty care business 

Strategic alliance to address the rapidly growing health and beauty care market

Expected synergies between world-class laser therapy device technology and biomaterials technology

LAMEDITECH, a leading laser treatment device company, announced on the 4th that it has signed a strategic partnership agreement with Xcell Therapeutics, a leading culture medium company, to advance its health and beauty care business (development of functional cosmetics and hair loss ampoules for laser beauty devices).

According to the company, Xcell Therapeutics is a company that developed the world's first GMP-grade Serum-Free Chemically Defined Media for hMSCs and has been recognized for its media technology both domestically and overseas. In particular, it owns and operates a GMP-grade production plant in Yongin that can produce 100,000 liters per year.

In particular, in recognition of its excellent technology, it was selected as a bio-innovative company in 2020 and won the Minister of Trade, Industry and Energy Award, and last year, it obtained the New Excellent Product certification, which is the most prestigious certificate issued by the Korean government.

Based on the signing of this business agreement, the two companies plan to actively respond to the domestic and international health and beauty care markets, which are growing rapidly year by year. A company official said, "The main content of the cooperation is to develop functional cosmetics that can be incorporated into laser beauty devices developed by LAMEDITECH and hair loss ampoules with hair loss prevention functions by Xcell Therapeutics."

At the signing ceremony, LAMEDITECH CEO Choi Jong-seok said, "We are pleased to pioneer the market with a domestic company that has proven its innovative technology." "We will coordinate our strengths so that we can create practical results not only in Korea but also overseas," he said.

The two companies plan to enhance market competitiveness by securing stability and functionality through synergy between LAMEDITECH's laser therapy device manufacturing technology and Xcell Therapeutics' media manufacturing technology know-how.

"I think this is a great opportunity to show the scalability of Xcell Therapeutics' technology," said Lee Yi-il, CEO of Xcell Therapeutics. "We will do our best to create a successful cooperation model between technology-based ventures."

Meanwhile, LAMEDITECH is not only advancing its global expansion through domestic MFDS approval, European CE, U.S. Food and Drug Administration (FDA) approval, and leading overseas certifications such as Brazil's National Sanitary Surveillance Agency (ANVISA), but is also growing as a laser-based healthcare company by being selected as a 2019 Health New Technology (NET), 2020 Excellent R&D Innovative Product, and National Innovative Company.

Its flagship product, 'Handy Ray', a laser blood collection device, is recognized for its painlessness and high hygiene. Based on this, we are conducting related clinical trials at Ko Daegu Medical Center, Ansan Medical Center, and Gacheon University Hospital, and have signed export contracts with 13 countries including Italy and Indonesia for a total of $15 million in recognition of our technology overseas.

With its other flagship products, 'PURAXEL' and 'CAREVEAM', it is in the process of entering the global beauty and laser treatment market with product miniaturization and price competitiveness.

source : https://newsis.com/view/?id=NISX20220204_0001747057&cID=10401&pID=10400